WeightControl.com Interview with:
Louis J Aronne M.D.
Sanford I. Weill Professor of Metabolic Research
Department of Medicine
Weill Cornell Medicine
WeightControl.com: What is the background for this study? What are the main findings?
Response: The SURMOUNT -4 trial demonstrates that patients who discontinued tirzepatide after losing 20.9% over 36 weeks regained about half the weight in one year to an average 9.5% weight loss following discontinuation while those who continued lost an additional 5%.
The metabolic parameters which had improved with weight loss returned towards their starting point, but did not completely regress.
WeightControl.com: What should readers take away from your report?
Response: Obesity is a chronic disease, like diabetes and hypertension. If treatment is discontinued, it will relapse, though gradually.
WeightControl.com: What recommendations do you have for future research as a result of this work?
Response: Besides continuing the medication, which is clearly effective, are there other strategies which could help with weight maintenance? For example, would a more intensive behavioral program or a lower dose of tirzepatide enable maintenance of the weight loss.
Disclosures: My disclosures are on this page: https://vivo.weill.cornell.edu/display/cwid-ljaronne
I am a paid consultant and member of a scientific advisory board for Lilly and several other companies.
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity The SURMOUNT-4 Randomized Clinical Tria
Citation:
Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. Published online December 11, 2023. doi:10.1001/jama.2023.24945
The information on WeightControl.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on December 11, 2023 by weightcontrol